BTMD biote Corp.
FY2025 10-K
biote Corp. (BTMD) filed its fiscal year 2025 10-K annual report with the SEC on Mar 13, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: hormone optimization training and Biote-branded dietary supplements sold to Biote-certified practitioners and partnered clinics
- • Strategic emphasis on managing risks related to outsourcing facilities that compound bioidentical hormones, including recent acquisition of Asteria Health (Mar 2024)
Risk Factors
- • Regulatory risk from potential liability and recalls linked to compounded drug formulations via outsourcing facilities, posing reputational harm
- • Macroeconomic exposure from 2.5% revenue decline to $192.2M in 2025 due to slowdown in new clinic additions and procedure volumes
Financial SummaryXBRL
Revenue
$192M
Net Income
$27M
Operating Margin
18.5%
Net Margin
14.1%
ROE
-46.2%
Total Assets
$108M
EPS (Diluted)
$0.74
Operating Cash Flow
$35M
Source: XBRL data from biote Corp. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on biote Corp.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.